Promoted Content Promoted Content


Find FDA Investigational New Drug (IND) Submissions for Oncology in CHINA


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CT120

            Therapeutic Area: Oncology Product Name: CT120

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 07, 2021


            CT120 is an autologous dual-target CAR-T therapy. Its extra cellular domain contains two fully-human scFv sequences that can specifically recognize CD19 and CD22. CT120 is developed on IASO Bio’s fully human antibody platform IMARS and CAR-T drug selection platform.